+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peptide and Oligonucleotide CDMO Market Forecast to 2033

  • PDF Icon

    Report

  • 150 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 6189374
REQUEST CUSTOMIZATION
Description Jump to:
The global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 12.75% from 2025 to 2033. The market is driven due to increasing demand for complex and targeted therapeutics, growing investment in biologics and nucleic acid-based drug development, rising outsourcing trends among pharmaceutical and biopharmaceutical companies, and advancements in synthesis and delivery technologies for peptides and oligonucleotides.

In addition, oligonucleotides and peptides have shown potential in treating a wide range of ailments, including metabolic disorders, cancer, and genetic diseases. Innovations in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have made it easier to produce and design complex molecules. This has substantially increased the applications of peptides and oligonucleotides in therapeutic usage and thus boosted the demand for contract development and manufacturing organizations (CDMOs) with specialized proficiency in these areas.

Furthermore, the rising trend toward personalized medicine has driven the need for customized peptide and oligonucleotide therapies, thereby supporting the demand for CDMOs that are vital in the production and development of these personalized treatment therapies. Moreover, regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have diligently worked on establishing guidelines for the manufacturing and development of oligonucleotides and peptides. Hence, the aforementioned factors are responsible for the lucrative growth of the market.

Global Peptide And Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global peptide and oligonucleotide CDMO market report based on product, service, end use, and region.

Product Outlook (Revenue, USD Million, 2021-2033)

  • Peptides
  • Oligonucleotides

Service Outlook (Revenue, USD Million, 2021-2033)

  • Contract Development
  • Contract Manufacturing

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights
Chapter 3. Peptide and Oligonucleotide CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Peptide and Oligonucleotide CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Supply Chain Analysis
3.7. Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Peptide and Oligonucleotide CDMO Market Product Movement Analysis
4.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Peptides
4.4.1. Peptides Market Estimates and Forecasts, 2021-2033 (USD million)
4.5. Oligonucleotides
4.5.1. Oligonucleotides Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Peptide and Oligonucleotide CDMO Market Service Movement Analysis
5.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
5.4. Contract Development
5.4.1. Contract Development Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Contract Manufacturing
5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Peptide and Oligonucleotide CDMO Market End Use Movement Analysis
6.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical Companies
6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Biopharmaceutical Companies
6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Others
6.6.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Europe Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. South Korea Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. MEA
7.8.1. MEA Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Peptide and Oligonucleotide CDMO Market Share Analysis, 2024
8.3. Company Profiles
8.3.1. PolyPeptide Group
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Product/Service Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. STA Pharmaceutical Co. Ltd.
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Product/Service Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Bachem
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Product/Service Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Creative Peptides
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product/Service Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Aurigene Pharmaceutical Services Ltd.
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product/Service Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Merck KGaA
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product/Service Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. EUROAPI
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product/Service Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Curia Global, Inc.
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product/Service Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. CordenPharma
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product/Service Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Sylentis, S.A.
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product/Service Benchmarking
8.3.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 4 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 5 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 6 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 7 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 8 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 9 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 10 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 11 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 12 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 13 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 14 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 15 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 16 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 17 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 18 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 19 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 20 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 21 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 22 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 23 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 24 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 25 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 26 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 27 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 28 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 29 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 30 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 31 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 32 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 33 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 34 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 35 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 36 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 37 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 38 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 39 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 40 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 41 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 42 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 43 Asia-Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 44 Asia-Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 45 Asia-Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 46 Asia-Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 47 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 48 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 49 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 50 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 51 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 52 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 53 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 54 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 55 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 56 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 57 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 58 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 59 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 60 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 61 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 62 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 63 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 64 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 65 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 66 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 67 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 68 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 69 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 70 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 71 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 72 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 73 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 74 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 75 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 76 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 78 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 80 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 81 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 82 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 83 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 84 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 86 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 87 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 88 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 89 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 90 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 91 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 92 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 93 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
Table 94 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021-2033 (USD Million)
Table 95 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 96 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021-2033 (USD Million)
List of Figures
Figure 1 Peptide and Oligonucleotide CDMO Market Segmentation
Figure 2 Market Research Process
Figure 3 Information Procurement
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Market Formulation & Validation
Figure 7 Commodity Flow Analysis
Figure 8 Value-Chain-Based Sizing & Forecasting
Figure 9 QFD Model Sizing & Forecasting
Figure 10 Bottom-up Approach
Figure 11 Market Snapshot
Figure 12 Segment Snapshot
Figure 13 Segment Snapshot
Figure 14 Segment Snapshot
Figure 15 Competitive Landscape Snapshot
Figure 16 Parent Market Outlook, 2024 (USD Million)
Figure 17 Ancillary Market Outlook, 2024 (USD Million)
Figure 18 Peptide and Oligonucleotide CDMO Market Dynamics
Figure 19 Porter’s Five Forces Analysis
Figure 20 PESTEL by SWOT Analysis
Figure 21 Peptide and Oligonucleotide CDMO Market Product Outlook: Segment Dashboard
Figure 22 Peptide and Oligonucleotide CDMO Market, by Product Segment: Market Share, 2025 & 2033
Figure 23 Peptides Market Estimates and forecasts, 2021-2033 (USD Million)
Figure 24 Oligonucleotides Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 25 Peptide and Oligonucleotide CDMO Market Service outlook: Segment dashboard
Figure 26 Peptide and Oligonucleotide CDMO Market, by Service Segment: Market Share, 2025 & 2033
Figure 27 Contract Development Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 28 Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 29 Peptide and Oligonucleotide CDMO Market End Use Outlook: Segment Dashboard
Figure 30 Peptide and Oligonucleotide CDMO Market, by End Use Segment: Market Share, 2025 & 2033
Figure 31 Pharmaceutical Companies Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 32 Biopharmaceutical Companies Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 33 Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 34 Regional marketplace: Key Takeaways
Figure 35 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 36 Key country dynamics
Figure 37 U S Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 38 Key country dynamics
Figure 39 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 40 Key country dynamics
Figure 41 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 42 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 43 Key country dynamics
Figure 44 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 45 Key country dynamics
Figure 46 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 47 Key country dynamics
Figure 48 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 49 Key country dynamics
Figure 50 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 51 Key country dynamics
Figure 52 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 53 Key country dynamics
Figure 54 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 55 Key country dynamics
Figure 56 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 57 Key country dynamics
Figure 58 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 59 Asia-Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 60 Key country dynamics
Figure 61 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 62 Key country dynamics
Figure 63 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 64 Key country dynamics
Figure 65 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 66 Key country dynamics
Figure 67 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 68 Key country dynamics
Figure 69 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 70 Key country dynamics
Figure 71 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 72 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 73 Key country dynamics
Figure 74 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 75 Key country dynamics
Figure 76 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 78 Key country dynamics
Figure 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 80 Key country dynamics
Figure 81 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 82 Key country dynamics
Figure 83 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 84 Key country dynamics
Figure 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 86 Key country dynamics
Figure 87 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 88 Key country dynamics
Figure 89 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021-2033 (USD Million)
Figure 90 Market Participant Categorization
Figure 91 Heat Map Analysis

Companies Mentioned

The companies profiled in this Peptide and Oligonucleotide CDMO market report include:
  • Solvay
  • Ensinger
  • 3DXTech
  • Essentium
  • ARMOR GROUP
  • IEMAI 3D
  • Shandong Kaisheng New Materials Co., Ltd.
  • Lehmann & Voss
  • INTAMSYS Technology Co. Ltd.
  • DELRAY Systems

Table Information

Report AttributeDetails
No. of Pages150
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 2.8 Billion
Forecasted Market Value ( USD ) by 2033 $ 8.14 Billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report 2025 - Product Image

Peptide and Oligonucleotide CDMO Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029 - Product Image

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029

  • Report
  • 255 Pages
  • Global
From
Active Pharmaceutical Ingredients CDMO Market - Global Forecast 2025-2032 - Product Image

Active Pharmaceutical Ingredients CDMO Market - Global Forecast 2025-2032

  • Report
  • 195 Pages
  • Global
From
Pharmaceutical CDMO & Contract Manufacturing Services Market - Global Forecast 2025-2030 - Product Image

Pharmaceutical CDMO & Contract Manufacturing Services Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.